Status:

UNKNOWN

Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients

Lead Sponsor:

Associazione Salentina Angela Serra

Conditions:

Chemotherapy Induced Nausea and Vomiting

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The aim of present study is to evaluate if the addition of Aprepitant to multiple doses of palonosetron IV enhances the efficacy of multiple doses of palonosetron IV alone, in preventing CINV in AML o...

Detailed Description

This is an open-label, randomized, comparative, multicenter phase II study in patients with AML scheduled to receive multiple days chemotherapy. Patients will receive either PALO+APR or the PALO regi...

Eligibility Criteria

Inclusion

  • Diagnosis of Acute Myeloid Leukaemia or High-risk MDS according to IPSS
  • Patient eligible for AML-like induction therapy
  • Candidate for multiple-days chemotherapy (minimum 3 days)
  • Age more, equal18 years
  • ECOG 0-2
  • Not pregnant or nursing
  • Must be able to complete the patient's diary
  • Provide written informed consent

Exclusion

  • AML or HR-MDS therapy-related
  • Active infection requiring intravenous antibiotics
  • Prior malignancies at other sites except surgically treated non-melanoma skin cancer, prostate cancer, superficial cervical cancer, or other cancer from which the patient had been disease-free for more/equal 5 years
  • Unacceptable hepatic function (more of 2 times the upper limit of normal for liver transaminases) and renal function (creatinine more of 1.5 times the upper limit of normal) unless disease-related
  • Myocardial infarction within the past 6 months
  • Psychiatric or CNS disorders interfering with ability to comply with study protocol
  • Known hypersensitivity to 5-HT3 antagonists and their components CSF involvement
  • Pre-existing nausea or vomiting

Key Trial Info

Start Date :

October 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2014

Estimated Enrollment :

134 Patients enrolled

Trial Details

Trial ID

NCT02205164

Start Date

October 1 2011

End Date

October 1 2014

Last Update

July 31 2014

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Università-Azienda Policlinico di Bari

Bari, BA, Italy, 70124

2

Ospedale Perrino

Brindisi, BR, Italy, 72010

3

Ospedale Pugliese-Ciacco

Catanzaro, CZ, Italy, 88100

4

IRCCS Casa Sollievo della Sofferenza

San Giovanni Rotondo, FG, Italy, 71013